DAWN

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts for traders to stay updated on stock market movements.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Analyst Rating: Oppenheimer analyst Matthew Biegler maintained a Hold rating on Day One Biopharmaceuticals (DAWN), which closed at $11.82, while the consensus rating is a Strong Buy with a price target of $34.83.

Performance Metrics: Biegler has an average return of -9.7% and a success rate of 27.90% on his stock recommendations, with DAWN's one-year high at $18.07 and low at $11.13.

Quarterly Performance: Day One Biopharmaceuticals reported a quarterly loss of $0.69 per share, significantly worse than the expected loss of $0.35, while revenues reached $29.21 million, exceeding estimates by 7.74%.

Future Outlook: The company's earnings outlook appears favorable with a Zacks Rank #1 (Strong Buy), suggesting potential outperformance in the market despite its current underperformance compared to the S&P 500.

Earnings Report: Day One Biopharmaceuticals reported a FY GAAP EPS of -$1.02, missing expectations by $0.29, while revenue reached $131.16M, exceeding estimates by $8.64M.

Financial Position: As of December 31, 2024, the company held cash, cash equivalents, and short-term investments totaling $531.7 million.

Insider Trading Activity: Charles N II York, COO of $DAWN, sold 4,370 shares for approximately $52,278, marking a total of 13 insider sales with no purchases in the past six months.

Institutional Investor Movements: In the latest quarter, 87 institutional investors increased their holdings in $DAWN, while 88 reduced their positions.

Upcoming Conference Call: Day One Biopharmaceuticals will host a live conference call and webcast on February 25, 2025, to discuss its financial results and corporate progress for Q4 and full-year 2024.

Company Overview: Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases in both children and adults, aiming to introduce breakthrough medicines through its innovative "search & development" strategy.

Analyst Ratings Overview: Analysts have expressed bullish sentiments for Day One Biopharmaceuticals, Health Catalyst, and Axsome Therapeutics, with strong buy ratings and significant upside potential in their price targets.

Current Stock Performance: Day One Biopharmaceuticals has a target of $34.83, Health Catalyst at $9.20, and Axsome Therapeutics at $152.80, indicating optimism despite current share prices being near their 52-week lows.

Vanguard Small-Cap Value ETF Analysis: The Vanguard Small-Cap Value ETF (VBR) has an implied analyst target price of $229.43, indicating a potential upside of 12.65% from its current trading price of $203.66.

Notable Holdings with Upside Potential: Key holdings such as Day One Biopharmaceuticals (DAWN), AST SpaceMobile (ASTS), and Brc Inc (BRCC) show significant upside potential based on analysts' target prices, with DAWN having a target 188.52% higher than its recent price.

Company Presentation Announcement: Day One Biopharmaceuticals will have its CEO, Dr. Jeremy Bender, present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2024, with a live audio webcast available on their website.

Focus on Pediatric Cancer: The company is dedicated to developing targeted therapies for pediatric cancer, addressing the significant lack of treatment options and aiming to improve outcomes from the initial diagnosis onward.

Dr. Blackman's Retirement: Samuel Blackman, co-founder and Head of R&D at Day One Biopharmaceuticals, will retire at the end of 2024 but will remain as a strategic advisor while the company searches for his replacement.

Company's Mission and Achievements: Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric cancer, successfully acquiring and advancing tovorafenib through FDA approval under Dr. Blackman's leadership.

Company Announcement: Day One Biopharmaceuticals will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, with a live webcast available for viewing.

Company Mission: Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric cancer, aiming to address the significant lack of treatment options and improve outcomes for patients from the moment of diagnosis.

Carvana's Financial Performance: Carvana Co. shares surged 20.3% in pre-market trading after reporting third-quarter revenue of $3.66 billion and earnings of 64 cents per share, both exceeding analyst expectations.

Market Movements: Several stocks experienced significant pre-market gains, including Root, Inc. (+79.1%) and Remitly Global, Inc. (+20.7%), while others like Equillium, Inc. (-42%) and Office Properties Income Trust (-34%) saw notable declines following their quarterly results.

Real-time Trading Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them stay updated with real-time news alerts.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

Top Movers on Wall Street: Several stocks saw significant increases after earnings reports, with Root (ROOT) leading at a 70.4% rise, followed by Remitly Global (RELY) at 21.8%, and Carvana (CVNA) at 20.0%.

Stocks Declining After Earnings: Conversely, Aurora Innovation (AUR) experienced the largest drop at 14.0%, along with Acadia Healthcare (ACHC) down 13.7%, and Robinhood (HOOD) down 12.1%.

Analyst Ratings: Marc Frahm from TD Cowen and JonesTrading both maintained a Buy rating on Day One Biopharmaceuticals, with price targets of $34.00 and $39.00 respectively, citing strong Q3 revenue growth and FDA approval of their product Ojemda as key factors.

Company Overview: Day One Biopharmaceuticals is focused on developing targeted therapies for genetically defined cancers, particularly in pediatric patients, with its lead product candidate being DAY101, a selective kinase inhibitor.

Stock Performance Overview: DAWN's stock has a 52-week low of $9.67 and a high of $18.0699, with the last trade recorded at $14.83.

Market Analysis Note: The article includes a reference to other stocks that have recently crossed above their 200-day moving average.

Real-time Intelligence for Traders: Benzinga Pro offers fast and accurate stock market intelligence, helping traders stay informed and make winning trades daily.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

Stock Performance Overview: DAWN's stock has a 52-week low of $9.67 and a high of $18.0699, with the last trade recorded at $14.78.

Market Insights: The article hints at other stocks that have recently crossed above their 200-day moving average, indicating potential market trends.

Stock Offering Announcement: Day One Biopharmaceuticals has filed a prospectus to offer and sell up to 12,068,959 shares of common stock by selling stockholders.

Market Response and Future Outlook: Despite receiving FDA approval, there remains uncertainty regarding Day One Biopharma's future, although it has recently received a double upgrade from Bank of America based on the potential of its drug Ojemda.